LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma

David Oldach (Chapel Hill, United States of America), David Oldach, Carlos Luna, Peter Szabo, Ismail Mitha, Cristina Tanaseanu, Alexis Doreski, Carlos Barrera, Anita Das, Kara Keedy, Brian Jamieson, Prabhavathi Fernandes

Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Session: Respiratory infections: from basic science to clinical issues
Session type: Thematic Poster Session
Number: 2655
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
David Oldach (Chapel Hill, United States of America), David Oldach, Carlos Luna, Peter Szabo, Ismail Mitha, Cristina Tanaseanu, Alexis Doreski, Carlos Barrera, Anita Das, Kara Keedy, Brian Jamieson, Prabhavathi Fernandes. LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma. Eur Respir J 2015; 46: Suppl. 59, 2655

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006

Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015

Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005

Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011


Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016

Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013



Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009

Intravenous steroids in the treatment of community-acquired pneumonia (CAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004

Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004



Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001

Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis
Source: Eur Respir J 2010; 35: 858-864
Year: 2010



Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 566s
Year: 2003

Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005

Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004)
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Penetration of moxifloxacin in bronchial secretions in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 135-143
Year: 2003



Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012

A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013

Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008


Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial
Source: International Congress 2015 – Acute critical care: news from the ICU
Year: 2015